Tristel PLC · LSE:TSTL

Tristel — H1 2024 Earnings Presentation

21 slides from Tristel's earnings presentation, February 2024

  1. Slide 1: Tristel Plc Interim Results Investor Presentation

    Slide 1: Tristel Plc Interim Results Investor Presentation

    31 DECEMBER 2023 TRISTEL PLC INTERIM RESULTS INVESTOR PRESENTATION Paul Swinney, CEO Liz Dixon, CFO Heidi Allard, CFC 26-28 February 2024 1

  2. Slide 2: Our Company

    Slide 2: Our Company

    Our Company • Global infection prevention • Focus on healthcare • Unique proposition: chlorine dioxide Decontamination of medical Hospital surface disinfection: instruments by hand sporicidal efficacy & sustainability Simple, focussed, global opportunity 2

  3. Slide 3: Multiple Revenue Sources Within The Hospital

    Slide 3: Multiple Revenue Sources Within The Hospital

    Multiple Revenue Sources Within The Hospital Department Medical Device % of Group Area Surface % of Group revenue revenue Obs & gynae Trans-vaginal u/sound probes Mattresses Radiology Trans-rectal u/sound probes 38% IV Poles Hospital wide Skin-surface u/sound probes Trolleys ENT Nasendoscopes 20% Ho

  4. Slide 4: Financial Highlights

    Slide 4: Financial Highlights

    Financial Highlights • 20% growth in turnover to a record level of £20.9m (2022: £17.5m) • Overseas sales continue to grow, up 13% to £12.7m (2022: £11.2m) • Reported EBITDA up 21% to £4.7m (2022: £3.9m) • Adjusted* EBITDA up 18% to £5.4m (2022: £4.6m), a margin of 26% (2022: 26%) • Reported profit

  5. Slide 5: Operational Highlights

    Slide 5: Operational Highlights

    Operational Highlights • First manufacture and launch of Tristel ULT into the United States ultrasound market • Approval of Tristel ULT by Health Canada post period end • UK & EU Medical Device Regulation reviews of Cache Tank and Capsule successfully concluded and positive recommendation for UKCA a

  6. Slide 6: 10 Year H-O-H Sales Growth Record

    Slide 6: 10 Year H-O-H Sales Growth Record

    10 Year H-O-H Sales Growth Record 40,000 35,000 30,000 Sources of £3.4m 25,000 period on period growth: Revenue £'000 20,000 H2 • £1.5m volume H1 15,000 • £1.9m pricing 10,000 5,000 - 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 Y-o-y 14% 12% 19% 10% 18% 21% -2% 0% 16% 20% Growth rate 6

  7. Slide 7: Sales Growth by Geography

    Slide 7: Sales Growth by Geography

    Sales Growth by Geography Period on £m Geography 2023-24 2022-23 period % change change Direct Australasia 2.3 2.2 0.1 5% Direct China & Hong Kong 1.0 1.0 - - Direct Malaysia & Singapore 0.4 0.4 - - Direct Western Europe 3.0 2.7 0.3 11% Direct Central Europe 3.3 2.9 0.4 14% Direct Southern Europe 0.

  8. Slide 8: Sales Growth by Portfolio and Channel

    Slide 8: Sales Growth by Portfolio and Channel

    Sales Growth by Portfolio and Channel Period on £m Channel 2023-24 2022-23 Period % change change Tristel Hospital UK direct 6.6 4.6 2.0 43% Medical Device EMEA direct 6.6 5.8 0.8 14% Decontamination APAC direct 3.3 3.1 0.2 6% Worldwide distributors 1.8 1.2 0.6 50% 18.3 14.7 3.6 25% Cache Hospital U

  9. Slide 9: North America – Ultrasound Opportunity

    Slide 9: North America – Ultrasound Opportunity

    North America – Ultrasound Opportunity • Tristel ULT: high-level disinfectant for endo-cavity probes & skin surface transducers approved by both FDA and Health Canada • 50m ultrasound scans in North America require high-level disinfection annually • Translates to a US$100m p.a. Tristel/Parker revenu

  10. Slide 10: North America – Ultrasound Progress

    Slide 10: North America – Ultrasound Progress

    North America – Ultrasound Progress 2018-2023: Commercial partnership with Parker Laboratories developed for the manufacture and distribution of Tristel ULT in the USA and Canada June 2023: USA FDA approves Tristel ULT June 2023: Tristel ULT is launched at the American Infection Prevention Congress

  11. Slide 11: North America - Ophthalmology Opportunity

    Slide 11: North America - Ophthalmology Opportunity

    North America - Ophthalmology Opportunity • Devices touching cornea require high-level disinfection (Spaulding Classification) • Universally, they are only low-level disinfected • Eye-related infection risks well known: conjunctivitis affects ~ 6m people annually in United States • Devices are known

  12. Slide 12: North America – Ophthalmology Progress

    Slide 12: North America – Ophthalmology Progress

    North America – Ophthalmology Progress Canada: Canada Health approved Tristel OPH in June 2021 Innova Medical Ophthalmics, Toronto, appointed as national distributor for Canada in 2022 Alberta Health Services becomes first user 24 repeat users across Canada, 12% market penetration USA: 510(K) submis

  13. Slide 13: Product Development

    Slide 13: Product Development

    Product Development 3T platform: AI: Colour change technology: App-based Train, Trace and Capabilities incorporated into Visual indicators to ensure key Test tool to record all steps of the app for objective steps in the decontamination the decontamination process. verification that the key steps pr

  14. Slide 14: FY23 - FY25 Financial Targets

    Slide 14: FY23 - FY25 Financial Targets

    FY23 - FY25 Financial Targets • Sales growth in the range of 10% to 15% per annum as an annual average over three years • EBITDA margin (excluding share-based payment charge) of at least 25% Due to CEO succession new targets deferred until October 2024 14

  15. Slide 15: ESG Highlights

    Slide 15: ESG Highlights

    ESG Highlights • ESG strategy published • Carbon Zero target of 2030 and route to success defined • Carbon profiling of key products underway with packaging adjustments and reductions planned • Partnership with ESG consultants to ensure best practice adhered to • Recruitment into specialist sustaina

  16. Slide 16: Summary & Outlook

    Slide 16: Summary & Outlook

    Summary & Outlook • A record set of results on all levels • Significant growth opportunity in both portfolios • Profitable, cash generative, debt free, progressive dividend • Exciting future ahead Simple, focussed, global opportunity 16

  17. Slide 17: Any questions?

    Slide 17: Any questions?

    Tsidl Any questions? Tristel

  18. Slide 18: Appendix – Income Statement

    Slide 18: Appendix – Income Statement

    Period ended Period ended APPENDIX – INCOME STATEMENT 31.12.23 31.12.22 £’000 £’000 Turnover 20,943 17,463 Cost of sales (3,401) (3,322) Gross profit 17,542 14,141 Gross margin % 84% 81% Distribution expenses (274) (198) Administrative and distribution expenses less other operating income (11,833) (

  19. Slide 19: Appendix – Balance Sheet

    Slide 19: Appendix – Balance Sheet

    APPENDIX – BALANCE SHEET 31.12.23 31.12.22 Non-current assets £’000 £’000 Goodwill 5,152 5,325 Intangible assets 4,579 3,828 Property, plant and equipment 8,369 7,968 Deferred tax 626 1,058 18,726 18,179 Current assets Inventories 4,450 4,668 Trade and other receivables 6,226 6,394 Income tax receiv

  20. Slide 20: Appendix – Balance Sheet Continued

    Slide 20: Appendix – Balance Sheet Continued

    APPENDIX – BALANCE SHEET …Continued 31.12.23 31.12.22 Capital and reserves £’000 £’000 Share capital 475 473 Share premium account 14,530 14,010 Merger reserve 2,205 2,205 Foreign exchange reserve (215) 123 Retained earnings 14,127 12,095 Non-controlling interests 7 7 Total equity 31,129 28,913 Curr

  21. Slide 21: Appendix – Cash Flow Statement

    Slide 21: Appendix – Cash Flow Statement

    APPENDIX – CASH FLOW STATEMENT Period ended Period ended 31.12.23 31.12.22 £’000 £’000 Profit before tax 3,437 2,388 Add back non-cash items 1,997 2,121 Working capital movements (222) (316) Interest received 125 - Purchase of tangible fixed assets (218) (128) Purchase of intangible assets (300) (29

Source: Internet Archive copy of investors.tristel.com

More decks from Tristel PLC

All 32 Tristel decks